Giuseppe
Emeritus
[Source: Eurosurveillance, full page: (LINK). Abstract, edited.]
Eurosurveillance, Volume 18, Issue 42, 17 October 2013
Research articles
MULTIDRUG-RESISTANT TUBERCULOSIS IN UZBEKISTAN: RESULTS OF A NATIONWIDE SURVEY, 2010 TO 2011
D J Ulmasova 1, G Uzakova 2, M N Tillyashayhov 3, L Turaev 4, W van Gemert 5, H Hoffmann 6, M Zignol 5, K Kremer 7, T Gombogaram 8, J Gadoev 8, P du Cros 9, N Muslimova 4, A Jalolov 2, A Dadu 7, P de Colombani 7, O Telnov 10, A Slizkiy 10, B Kholikulov 1, M Dara 7, D Falzon 5
1 Republican DOTS Centre, Tashkent, Uzbekistan; 2 Programme Implementation Unit, The Global Fund to Fight AIDS, TB and Malaria (TGF), Tashkent, Uzbekistan; 3 National Institute of TB and Pulmonology, Tashkent, Uzbekistan; 4 National Reference Laboratory (NRL), Tashkent, Uzbekistan; 5 World Health Organization, Global TB Programme, Geneva, Switzerland; 6 Supranational TB Reference Laboratory (SRL Gauting), IML red GmbH, synlab Bayern, Asklepios Fachkliniken M?nchen-Gauting, Germany; 7 World Health Organization Regional Office for Europe, Copenhagen, Denmark; 8 World Health Organization Country Office, Tashkent, Uzbekistan; 9 M?decins Sans Fronti?res (MSF), London, United Kingdom; 10 M?decins Sans Fronti?res (MSF), Tashkent/Nukus, Uzbekistan
Citation style for this article: Ulmasova DJ, Uzakova G, Tillyashayhov MN, Turaev L, van Gemert W, Hoffmann H, Zignol M, Kremer K, Gombogaram T, Gadoev J, du Cros P, Muslimova N, Jalolov A, Dadu A, de Colombani P, Telnov O, Slizkiy A, Kholikulov B, Dara M, Falzon D. Multidrug-resistant tuberculosis in Uzbekistan: results of a nationwide survey, 2010 to 2011. Euro Surveill. 2013;18(42)
ii=20609. Available online: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20609
Date of submission: 30 January 2013
_________
Multidrug-resistant tuberculosis (MDR-TB; resistance to at least rifampicin and isoniazid) is a global public health concern. In 2010?2011, Uzbekistan, in central Asia, conducted its first countrywide survey to determine the prevalence of MDR-TB among TB patients. The proportion of MDR-TB among new and previously treated TB patients throughout the country was measured and risk factors for MDR-TB explored. A total of 1,037 patients were included. MDR-TB was detected in 165 treatment-na?ve (23.2%; 95% confidence interval (CI) 17.8%?29.5%) and 207 previously treated (62.0%; 95% CI: 52.5%?70.7%) patients. In 5.3% (95% CI: 3.1%?8.4%) of MDR-TB cases, resistance to fluoroquinolones and second-line injectable drugs (extensively drug resistant TB; XDR-TB) was detected. MDR-TB was significantly associated with age under 45 years (adjusted odds ratio: 2.24; 95% CI: 1.45?3.45), imprisonment (1.93; 95% CI: 1.01?3.70), previous treatment (4.45; 95% CI: 2.66?7.43), and not owning a home (1.79; 95% CI: 1.01?3.16). MDR-TB estimates for Uzbekistan are among the highest reported in former Soviet Union countries. Efforts to diagnose, treat and prevent spread of MDR-TB need scaling up.
-
------
Eurosurveillance, Volume 18, Issue 42, 17 October 2013
Research articles
MULTIDRUG-RESISTANT TUBERCULOSIS IN UZBEKISTAN: RESULTS OF A NATIONWIDE SURVEY, 2010 TO 2011
D J Ulmasova 1, G Uzakova 2, M N Tillyashayhov 3, L Turaev 4, W van Gemert 5, H Hoffmann 6, M Zignol 5, K Kremer 7, T Gombogaram 8, J Gadoev 8, P du Cros 9, N Muslimova 4, A Jalolov 2, A Dadu 7, P de Colombani 7, O Telnov 10, A Slizkiy 10, B Kholikulov 1, M Dara 7, D Falzon 5
1 Republican DOTS Centre, Tashkent, Uzbekistan; 2 Programme Implementation Unit, The Global Fund to Fight AIDS, TB and Malaria (TGF), Tashkent, Uzbekistan; 3 National Institute of TB and Pulmonology, Tashkent, Uzbekistan; 4 National Reference Laboratory (NRL), Tashkent, Uzbekistan; 5 World Health Organization, Global TB Programme, Geneva, Switzerland; 6 Supranational TB Reference Laboratory (SRL Gauting), IML red GmbH, synlab Bayern, Asklepios Fachkliniken M?nchen-Gauting, Germany; 7 World Health Organization Regional Office for Europe, Copenhagen, Denmark; 8 World Health Organization Country Office, Tashkent, Uzbekistan; 9 M?decins Sans Fronti?res (MSF), London, United Kingdom; 10 M?decins Sans Fronti?res (MSF), Tashkent/Nukus, Uzbekistan
Citation style for this article: Ulmasova DJ, Uzakova G, Tillyashayhov MN, Turaev L, van Gemert W, Hoffmann H, Zignol M, Kremer K, Gombogaram T, Gadoev J, du Cros P, Muslimova N, Jalolov A, Dadu A, de Colombani P, Telnov O, Slizkiy A, Kholikulov B, Dara M, Falzon D. Multidrug-resistant tuberculosis in Uzbekistan: results of a nationwide survey, 2010 to 2011. Euro Surveill. 2013;18(42)
ii=20609. Available online: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20609Date of submission: 30 January 2013
_________
Multidrug-resistant tuberculosis (MDR-TB; resistance to at least rifampicin and isoniazid) is a global public health concern. In 2010?2011, Uzbekistan, in central Asia, conducted its first countrywide survey to determine the prevalence of MDR-TB among TB patients. The proportion of MDR-TB among new and previously treated TB patients throughout the country was measured and risk factors for MDR-TB explored. A total of 1,037 patients were included. MDR-TB was detected in 165 treatment-na?ve (23.2%; 95% confidence interval (CI) 17.8%?29.5%) and 207 previously treated (62.0%; 95% CI: 52.5%?70.7%) patients. In 5.3% (95% CI: 3.1%?8.4%) of MDR-TB cases, resistance to fluoroquinolones and second-line injectable drugs (extensively drug resistant TB; XDR-TB) was detected. MDR-TB was significantly associated with age under 45 years (adjusted odds ratio: 2.24; 95% CI: 1.45?3.45), imprisonment (1.93; 95% CI: 1.01?3.70), previous treatment (4.45; 95% CI: 2.66?7.43), and not owning a home (1.79; 95% CI: 1.01?3.16). MDR-TB estimates for Uzbekistan are among the highest reported in former Soviet Union countries. Efforts to diagnose, treat and prevent spread of MDR-TB need scaling up.
-
------